Elicio Therapeutics, Inc. (ELTX) Balance Sheet

The consistent decline in equity reflects the cumulative impact of persistent operating losses that have eroded the capital base established during the reverse merger. This trajectory suggests that the company is increasingly reliant on external financing to offset the depletion of its net assets, leaving little room for operational missteps.

While the current ratio of 2.24 appears superficially healthy, it masks the reality of a high-burn environment where liquid assets are being consumed to support R&D. Investors should monitor the pace of cash depletion, as the current runway appears insufficient to reach meaningful clinical milestones without further dilutive capital raises.

The absence of retained earnings and the reliance on external funding suggest that the equity base is essentially a vehicle for financing R&D rather than a reflection of accumulated value. This structure implies that shareholders are effectively funding the clinical trial pipeline with little protection against the dilution inherent in biotech capital markets.